DIRECT COST OFFSETS RELATED TO BELIMUMAB SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN SPAIN

Author(s)

Cevey M1, Calvo-Alén J2, Crespo C3, Robles-Marhuenda A4, Cortés J5
1GlaxoSmithKline, Madrid, Spain, 2Hospital Universitario Araba, Vitoria, Spain, 3Universidad de Barcelona, Barcelona, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Vall d´Hebrón Institut de Recerca (VHIR), Barcelona, Spain

OBJECTIVES: To estimate the direct costs related to belimumab SC in the treatment of adult patients with Systemic Lupus Erythematosus (SLE) with high disease activity and auto-antibody-positive despite standard therapy.

METHODS: A pharmacoeconomic study was conducted for an average of 3,995 SLE patients over 5 years from Spanish National Health System perspective. The budget impact model compared the cost difference in each year under two market scenarios: current market (Standard Therapy (ST) and belimumab IV without belimumab SC) and other market, in which patients switched from belimumab IV to belimumab SC until reaching 17% of total market share. Patients' characteristics, rate of flares and severity, and healthcare consumption were evaluated. Flares per patient per year were based on RCT data (non-severe flares RR: 0.86, average 2.5 for patients on ST and 2.14 on belimumab; severe flares RR: 0.54, average 1.01 for patients on ST and 0.54 on belimumab). Epidemiological, clinical and resource use data were obtained from published literature and expert interviews. Deterministic sensitivity analysis was conducted.

RESULTS: ST encompassed 83% Corticosteroids, 83% Anti-Malarials, 52% Non-biological Immunosuppressives, 20% NSAIDs, 13% others Biologic Immunosuppressives, 2% Intravenous Immunoglobulins and 0.07% Therapeutic Plasma Exchange. Belimumab IV annual administration cost was 3,910.07€ for the first year and 3,388.72€ for the next years; and 205.62€ for ST. Based on 547.12€ per non-severe flare event, annual cost of non-severe flares for ST patients was 1,367.81€ and 1,172.41€ for belimumab patients. Additionally, annual cost of severe flares for ST patients was 4,889.30€ and 2,640.22€ for belimumab patients (4,840.89€ per event). On this basis the annual cost saving was estimated to be 2 million euros.

CONCLUSIONS: This study provides a health economic rationale related to belimumab SC prescription, due to the reduction of clinical events rate and direct cost savings.

This study was funded by GlaxoSmithKline (Study code: HO-17-18309).

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PSY62

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×